01—Abstract
Summary
Summary of the 8-K filed July 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Merck reported second-quarter 2024 results on July 30, 2024, with total sales of $16.1 billiona, up 7% reported and 11% excluding foreign exchange.
KEYTRUDA was the clear growth engine at $7.3 billionb (up 16%, or 21% ex-FX), driven by earlier-stage indications such as triple-negative breast cancer and renal cell carcinoma. Profitability was strong: GAAP EPS was $2.14 versus a loss of $2.35 a year earlier, which included a $4.02 per share Prometheus charge, and non-GAAP EPS was $2.28. The quarter also benefited from a $259 million tax reserve release tied to the expiration of a statute of limitations for the 2019 tax year, which flattered the GAAP and non-GAAP tax lines and should be treated as non-recurring.
The full-year 2024 sales outlook was raised and narrowed to $63.4 to $64.4 billionc from $63.1 to $64.3 billion, despite a softer quarter for GARDASIL in China caused by distributor sell-out timing. However, non-GAAP EPS guidance was cut sharply to $7.94 to $8.04 from $8.53 to $8.65. The reduction reflects a one-time $1.3 billion (about $0.51 per share) charge for the EyeBio acquisition, plus about $0.26 per share for Harpoon and roughly $0.09 per share of financing and asset-advancement expense, and a higher expected non-GAAP tax rate of 15.5% to 16.5%.
Investors should therefore read the EPS cut as largely acquisition-driven rather than a deterioration in underlying demand. On the pipeline side, the filing highlights the U.S. launch of WINREVAIR (over 1,000 patients treated by end of June), FDA approval of the CAPVAXIVE pneumococcal vaccine with a unanimous ACIP recommendation, positive Phase 2b/3 data for clesrovimab in infant RSV prevention, and a positive EU CHMP opinion for WINREVAIR. Offsetting pressures include continued erosion in JANUVIA/JANUMET (down 27%d and 27% in the quarter, respectively, on U.S. pricing and generic competition), BRIDION, and LAGEVRIO, as well as the Argentine peso devaluation that weighed on reported growth.
02—Key points
Key Highlights
- Q2 2024 sales rose 7% to $16.1 billion (11% excluding FX), with KEYTRUDA up 16% to $7.3 billion (21% ex-FX), accounting for roughly 45% of total sales.
- GAAP EPS of $2.14 compares with a GAAP loss of $2.35 in Q2 2023, which included a $4.02 per share Prometheus acquisition charge; non-GAAP EPS was $2.28.
- Q2 results include a $259 million (4.3 percentage point) tax benefit from releasing reserves for unrecognized tax benefits, which is non-recurring and lowered the effective tax rate to 9.1%.
- Full-year 2024 sales guidance was raised and narrowed to $63.4 to $64.4 billion, despite a China GARDASIL sell-out shortfall and an expected FX headwind of about 3 percentage points.
- Full-year non-GAAP EPS guidance was lowered to $7.94 to $8.04 from $8.53 to $8.65, primarily due to a $1.3 billion (about $0.51 per share) one-time EyeBio charge, with the non-GAAP tax rate also raised to 15.5% to 16.5%.
- WINREVAIR launched successfully in the U.S. with over 1,000 patients treated by end of June, and received a positive EU CHMP opinion; CAPVAXIVE received FDA approval and a unanimous ACIP recommendation.
- JANUVIA/JANUMET sales fell 27% and BRIDION fell 9% on U.S. pricing, demand, and generic erosion, while LAGEVRIO fell 46% as pandemic-related demand continued to normalize.
03—Questions
Frequently Asked Questions
Why did Merck cut its non-GAAP EPS guidance even though it raised its sales outlook?
The EPS reduction is driven mainly by one-time acquisition charges rather than weaker operations. The guidance now includes a $1.3 billion (about $0.51 per share) charge for the EyeBio acquisition, roughly $0.09 per share of financing and asset-advancement costs, and a higher expected non-GAAP tax rate because the EyeBio charge is not tax deductible. Sales guidance was raised, indicating underlying demand remains solid.
How much of Q2 2024 earnings was boosted by one-time tax benefits?
The quarter benefited from a $259 million tax benefit from reducing reserves for unrecognized tax benefits after the statute of limitations expired for the 2019 federal tax year. This added about 4.3 percentage points of favorable impact, reducing the GAAP effective tax rate to 9.1%. The benefit is excluded from non-GAAP EPS, so it does not inflate the $2.28 non-GAAP figure, but it does lift GAAP EPS of $2.14.
Is KEYTRUDA still driving Merck's growth?
Yes. KEYTRUDA sales reached $7.3 billion in Q2 2024, up 16% reported and 21% excluding FX, representing about 45% of total company sales. Growth came from earlier-stage indications such as triple-negative breast cancer and renal cell carcinoma, as well as non-small cell lung cancer in the U.S. The company also received FDA approval for KEYTRUDA in endometrial carcinoma, its 40th U.S. indication, and a Priority Review for mesothelioma with a September 25, 2024 PDUFA date.
Which products are facing the most pressure?
JANUVIA and JANUMET fell 27% on lower U.S. pricing and demand and generic competition abroad. LAGEVRIO declined 46% as demand and pricing eased in Asia Pacific. BRIDION fell 9% due to European and Asia Pacific generic competition. The filing also notes a lower GARDASIL sell-out in China, although GARDASIL sales still rose 1% globally on U.S. pricing and demand.
What acquisitions did Merck complete, and what do they mean for investors?
Merck completed the acquisitions of EyeBio (lead candidate Restoret/MK-3000 for retinal diseases including diabetic macular edema and wet AMD) and Elanco's aqua business in July 2024. It also converted its opevesostat collaboration with Orion into an exclusive global license. The EyeBio deal carries a $1.3 billion one-time charge, so investors should weigh it against the long-term potential of the retinal pipeline and the value of the newly licensed prostate cancer candidate.
04—Continue